[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2009074853A2 - Composition ophtalmique comprenant de la phényléphrine - Google Patents

Composition ophtalmique comprenant de la phényléphrine Download PDF

Info

Publication number
WO2009074853A2
WO2009074853A2 PCT/IB2008/002647 IB2008002647W WO2009074853A2 WO 2009074853 A2 WO2009074853 A2 WO 2009074853A2 IB 2008002647 W IB2008002647 W IB 2008002647W WO 2009074853 A2 WO2009074853 A2 WO 2009074853A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
agent
sodium
group
range
Prior art date
Application number
PCT/IB2008/002647
Other languages
English (en)
Other versions
WO2009074853A3 (fr
Inventor
Honey Bala
Rahul Hasija
Sateesh Kumar Chauhan
Deepak Bahri
Original Assignee
Promed Research Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40755940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009074853(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Promed Research Centre filed Critical Promed Research Centre
Publication of WO2009074853A2 publication Critical patent/WO2009074853A2/fr
Publication of WO2009074853A3 publication Critical patent/WO2009074853A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the present invention provides an ophthalmic composition for topical application comprising a mydriatic agent and a viscoelastic polymer, and also methods of preparing such a composition for human and veterinary administration.
  • the dilatation of pupil has different indications e.g. fundus examinations, old age refractions, for visual gain in cataract etc.
  • Mydriasis-use of phenylephrine (a dose-response concept) , Chawdhary S, Angra SK, Zutshi R, Sachdev MS, Indian Journal of Ophthamology, 1984, vol 32, issue 4, 213 -16)
  • Phenylephrine is recommended as a vasoconstrictor, decongestant and mydriatic for a wide variety of ophthalmic conditions and procedures.
  • a mydriatic is an agent which induces dilation of the pupil. Some of its uses are for pupillary dilation in uveitis, for many surgical procedures and for refraction without cycloplegia. It may also be used
  • Phenylephrine is a very unstable compound in solution and is found to degrade in the presence of light and upon atmospheric contact. Phenylephrine hydrochloride and solutions containing the drug are subject to oxidation and should be stored in tight, light-resistant containers. Solutions of the drug must not be used if they are brown or contain a precipitate. However, oxidation of the drug resulting in loss of activity may occur without a color change being evident. In the prior art, various compositions comprising phenylephrine have been prepared. However, none address problem of oxidation.
  • An object of the present invention is to provide an ophthalmic composition comprising phenylephrine, a mydriatic agent and a viscoelastic agent.
  • Yet another object of the invention is to provide a process for the preparation of the ophthalmic drug.
  • the present invention provides an ophthalmic composition
  • phenylephrine a viscoelastic agent, an osmolality agent, an ophthalmically acceptable salt, a buffering agent and water.
  • the phenylephrine may be present in the range of 0.15%w/v - 10% w/v.
  • Phenylephrine may be in the form of pharmaceutically acceptable salt such as the salt of inorganic acid hydrochloride, bicarbonate, sulfate, nitrate etc or salt of organic acid such as tartarate, acetate, etc.
  • the composition comprises a viscoelastic agent that is preferably selected from the group of carboxyl methyl cellulose, poly vinyl alcohol, hydroxy propyl methyl cellulose (HPMC), hydroxy ethyl cellulose, povidone, dextran, etc.
  • a viscoelastic agent that is preferably selected from the group of carboxyl methyl cellulose, poly vinyl alcohol, hydroxy propyl methyl cellulose (HPMC), hydroxy ethyl cellulose, povidone, dextran, etc.
  • HPMC hydroxy propyl methyl cellulose
  • HPMC hydroxy ethyl cellulose
  • povidone povidone
  • dextran etc.
  • the amount of the viscoelastic agent, i.e. such as HPMC contained in the composition is 0.1-3%, preferably 0.2-1%, and most preferably 0.2-0.5%.
  • the viscosity of the composition of the present invention may be 0.1-10 cps, preferably 0.5-5 cps, and most preferably 1-3 cps. This relatively low viscosity ensures that the product is comfortable, does not cause blurring, and is easily processed during manufacturing, transfer and filling operations
  • the composition optionally further includes at least one ophthalmically acceptable salt in an amount required to bring osmolality of the composition into an ophthalmically acceptable range.
  • ophthalmically acceptable salt include those having sodium, potassium or ammonium cation and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anion; preferred salt include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate, with sodium chloride being especially preferred.
  • solutes suitable for adjustment of osmolality include sugar, for example dextrose, lactose, xylitol, mannitol and glycerine.
  • composition as described herein above also comprises a buffering agent and/or an agent for adjusting osmolality in amounts whereby the solution is substantially isotonic and has a physiologically acceptable pH.
  • composition also includes an agent for normalizing the osmolality such as sodium citrate.
  • Ophthalmicaly acceptable osmolality lies within the limits of 150-1150 mOsm, preferably within 250-450 mOsm, most preferably within the limits of 300-400 mOsm
  • the composition of the invention optionally further includes at least one ophthalmically.
  • acceptable pH adjusting agent and/or buffer including an acid such as acetic, boric, citric, lactic, phosphoric and hydrochloric acid; a base such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane, triethanolamine; and a buffer such as citrate/dextrose, sodium bicarbonate and ammonium chloride, or an amino acid.
  • an acid, base and/or buffer is preferably included in an amount required to maintain pH of the composition in an ophthalmically acceptable range.
  • the pH of the composition of the present invention may be between 3-8, preferably within the range of 4-7 and most preferably in the range of 4.0-5.5.
  • the amount of salt, buffer required for adjusting the osmolality and the pH, respectively is well known to those skilled in the art.
  • composition of the present invention is preferably packaged in opaque plastic container, one that can be presented in the form of eye drops packed in glass vial preferably amber colored, BFS plastic vial desirably opaque or three-piece plastic vial preferably opaque.
  • composition of the present invention may be prepared by a process comprising
  • a solution of HPMC, buffering agent and osmolality agent may be prepared by simple admixture, with agitation as appropriate, of the ingredients. Buffering agents and agents for adjustment of osmolality can be added at any stage but are preferably present in solution with the HPMC before addition of the Phenylephrine
  • the aqueous solution containing HPMC 5 buffering agent and osmolality agent is first prepared, and the Phenylephrine is added to that solution with agitation until it is fully dissolved.
  • Processes for preparing an ophthalmic composition of the invention are preferably conducted in a sterile environment so as to provide a sterile product.
  • composition of the type as illustrated by the present invention has been found to be - substantially stable and efficacious to the compositions without viscoelastic agent.
  • Example 2 Effect of composition on dilation of eye in rabbits.
  • Example 1 The composition of Example 1 was prepared. Another composition similar to that of Example 1 was prepared but, without HPMC. The effect of composition with HPMC was compared with the composition without HPMC. The mydriatic effect of the composition was studied by examining the pupil dilatation activity in New Zealand albino rabbits weighing about 2.5-3 kg and is given in Table I.
  • the rabbits were divided in to two groups of 6 each. Left eye of each rabbit was kept as control and one drop of 0.9% sodium chloride isotonic saline solution was instilled. In the right eye one drop of composition of present invention with viscoelastic and without viscoelastic agent was instilled. The pupil size, light reflux, corneal reflux and state of conjunctiva was observed and recorded at 0 minute (Control value), 15 min, 30 min, 45 min, 60 min, then at hourly interval for 6 hrs. The results are provided in table " 1. '
  • the above table measures dilation of the pupil and the time required for dilation of the pupil.
  • An increase in the value of dilation and decrease in the time required for dilation shows enhanced efficacy of the composition.
  • the period of peak dilation indicates the duration of efficacy of the drug while the time to reach peak dilation is indicated by time of peak dilation. Lower the peak dilation time indicates the higher efficacy.
  • Example 3 It was found that addition of HPMC improves the appearance and controls the level of impurities in the phenylepherine composition and hence it increased the overall shelf life of the product as described in Table -2

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention se réfère à une composition ophtalmique stable et efficace pour application topique qui comprend un agent mydriatique et un polymère viscoélastique, et à des procédés de préparation d'une telle composition destinée à une usage humain et vétérinaire.
PCT/IB2008/002647 2007-12-10 2008-10-07 Composition ophtalmique comprenant de la phényléphrine WO2009074853A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2583/DEL/2007 2007-12-10
IN2583DE2007 2007-12-10

Publications (2)

Publication Number Publication Date
WO2009074853A2 true WO2009074853A2 (fr) 2009-06-18
WO2009074853A3 WO2009074853A3 (fr) 2009-08-06

Family

ID=40755940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002647 WO2009074853A2 (fr) 2007-12-10 2008-10-07 Composition ophtalmique comprenant de la phényléphrine

Country Status (2)

Country Link
RU (1) RU2600863C2 (fr)
WO (1) WO2009074853A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012117115A3 (fr) * 2011-03-03 2013-01-10 Croma-Pharma Gmbh Utilisation d'un fluide viscoélastique pour la préparation d'un produit médical pour le traitement chirurgical de l'oeil
RU2601115C2 (ru) * 2011-04-22 2016-10-27 Алькон Рисерч, Лтд. Офтальмологическая композиция с повышающей вязкость системой, содержащей два различных средства повышения вязкости
US20200085766A1 (en) * 2013-11-14 2020-03-19 Paragon BioTeck, Inc. Methods and compositions of stable phenylephrine formulations
WO2021150747A1 (fr) * 2020-01-22 2021-07-29 Nevakar Inc. Compositions et récipients de chlorhydrate de phényléphrine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
WO2002024116A1 (fr) * 2000-09-20 2002-03-28 Shahinian, Lee, Jr. Préparations et médications nasales, inhalables et ophtalmiques locales à conservation spontanée
EP1283043A1 (fr) * 2000-05-17 2003-02-12 Senju Pharmaceutical Co., Ltd. Composition ophtalmique
US20030203034A1 (en) * 2002-04-26 2003-10-30 Allergan Sales, Inc. Compositions for treating hyperemia
US20060110331A1 (en) * 2004-11-24 2006-05-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
WO2007127333A2 (fr) * 2006-04-26 2007-11-08 Aciex, Inc. Compositions pour le traitement et la prévention du gonflement des paupières
US20080050335A1 (en) * 2006-07-25 2008-02-28 Osmotica Corp. Ophthalmic Solutions
WO2008026756A1 (fr) * 2006-08-28 2008-03-06 Senju Pharmaceutical Co., Ltd. Préparation ophtalmique du type à absorption par voie percutanée

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0694310B1 (fr) * 1993-04-16 2000-02-16 Wakamoto Pharmaceutical Co., Ltd. Composition medicamenteuse se tranformant en gel thermiquement de fa on reversible
KR100246016B1 (ko) * 1993-04-30 2000-04-01 피르 포겔 안과용 합성 점탄성 물질
BRPI0517451A (pt) * 2004-10-25 2008-10-07 Bausch & Lomb composição oftámilca, e, métodos de tratar conjutivite alérgica e doença de olho seco
RU2284181C2 (ru) * 2004-11-11 2006-09-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Федерального агентства по здравоохранению и социальному развитию (ФГУ "МНТК"МГ"им. акад. С.Н. Федорова Росздрава") Фармацевтическая композиция для профилактики инфекции в офтальмологии "интрависк"

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
EP1283043A1 (fr) * 2000-05-17 2003-02-12 Senju Pharmaceutical Co., Ltd. Composition ophtalmique
WO2002024116A1 (fr) * 2000-09-20 2002-03-28 Shahinian, Lee, Jr. Préparations et médications nasales, inhalables et ophtalmiques locales à conservation spontanée
US20030203034A1 (en) * 2002-04-26 2003-10-30 Allergan Sales, Inc. Compositions for treating hyperemia
US20060110331A1 (en) * 2004-11-24 2006-05-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
WO2007127333A2 (fr) * 2006-04-26 2007-11-08 Aciex, Inc. Compositions pour le traitement et la prévention du gonflement des paupières
US20080050335A1 (en) * 2006-07-25 2008-02-28 Osmotica Corp. Ophthalmic Solutions
WO2008026756A1 (fr) * 2006-08-28 2008-03-06 Senju Pharmaceutical Co., Ltd. Préparation ophtalmique du type à absorption par voie percutanée

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012117115A3 (fr) * 2011-03-03 2013-01-10 Croma-Pharma Gmbh Utilisation d'un fluide viscoélastique pour la préparation d'un produit médical pour le traitement chirurgical de l'oeil
CN103547257A (zh) * 2011-03-03 2014-01-29 克罗马药品有限责任公司 粘弹性流体在生产用于通过手术治疗眼的药物产品中的应用
JP2014506911A (ja) * 2011-03-03 2014-03-20 クロマ−ファーマ ゲーエムベーハー 眼の外科処置用医薬製品を製造するための粘弾性流体の使用
RU2603489C2 (ru) * 2011-03-03 2016-11-27 ВАЛЕАНТ сп.з. о.о. сп. й. Применение вязкоэластичной жидкости для получения медицинского продукта для хирургического лечения глаз
RU2601115C2 (ru) * 2011-04-22 2016-10-27 Алькон Рисерч, Лтд. Офтальмологическая композиция с повышающей вязкость системой, содержащей два различных средства повышения вязкости
US20200085766A1 (en) * 2013-11-14 2020-03-19 Paragon BioTeck, Inc. Methods and compositions of stable phenylephrine formulations
US11957646B2 (en) * 2013-11-14 2024-04-16 Paragon BioTeck, Inc. Methods and compositions of stable phenylephrine formulations
WO2021150747A1 (fr) * 2020-01-22 2021-07-29 Nevakar Inc. Compositions et récipients de chlorhydrate de phényléphrine

Also Published As

Publication number Publication date
WO2009074853A3 (fr) 2009-08-06
RU2010128222A (ru) 2012-01-20
RU2600863C2 (ru) 2016-10-27

Similar Documents

Publication Publication Date Title
CN102046149B (zh) 稳定的眼药制剂
TW200402B (fr)
US20140228364A1 (en) Ophthalmic Compositions Comprising Prostaglandin F2 Alpha Derivatives and Hyaluronic Acid
JP2020007356A (ja) アトロピン含有水性組成物
JP2023153926A (ja) 交差架橋剤、及び関連する方法
WO2017066052A1 (fr) Formulations et méthodes de traitement de pression intraoculaire élevée
JP2021046394A (ja) ブリモニジンとチモロールとを含む、緑内障罹患患者における眼圧を下降させるための組成物
CN114129575A (zh) 一种药物组合物的制备方法和应用
JP2021509902A (ja) 近視進行の治療
WO2009074853A2 (fr) Composition ophtalmique comprenant de la phényléphrine
JP2021191802A (ja) 眼疾患を処置するためのオキシメタゾリン組成物および方法
JP7250685B2 (ja) ピリジルアミノ酢酸化合物を含有する医薬
CN103977011A (zh) 含有曲伏前列素和噻吗洛尔的眼用凝胶剂及其制备方法
TW202114697A (zh) 用於穩定包括藥物的水性組成物之pH值的方法
CN105213418A (zh) 一种眼科术前用复方滴眼液及其制备方法
KR20230145458A (ko) 우르소데옥시콜산 또는 그 염을 함유하는 수성 의약 조성물
US20100323978A1 (en) Non-aqueous oil delivery system for ophthalmic drugs
US20240122974A1 (en) Treatment of myopia
CN110200904A (zh) 一种降眼压缓释滴眼组合物及其制备方法
US20240307355A1 (en) Pharmaceutical compositions comprising apraclonidine for ocular redness relief
CN104873519B (zh) 一种曲伏前列素眼用组合物及其制备方法
EP4368179A1 (fr) Composition contenant du loxoprofène sodique
CN116898800A (zh) 无防腐剂的眼科药物乳剂及其应用
CN117618333A (zh) 一种更昔洛韦眼用制剂及其制备方法
CN116459251A (zh) 一种含西维美林的眼用制剂及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08858901

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010128222

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 08858901

Country of ref document: EP

Kind code of ref document: A2